Latest news with #REYOBIQ
Business Insider
26-06-2025
- Business
- Business Insider
Why Is Plus Therapeutics Stock (PSTV) Up 100% Today?
Plus Therapeutics (PSTV) stock saw a huge rally on Wednesday as the clinical-stage pharmaceutical company received approval from the Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for REYOBIQ. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter This approval covers the use of REYOBIQ as a potential treatment for pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma (HGG) and ependymoma. The company will conduct a clinical trial of this, with the U.S. Department of Defense providing a $3 million grant to fund the study. PSTV stock was up 103.69% in pre-market trading on Wednesday, following a 1.47% rally yesterday. However, the shares are down 83.74% year-to-date and have seen much volatility in 2025. This makes the stock a dangerous gambit not fit for risk-averse traders. Is Plus Therapeutics Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Plus Therapeutics is Strong Buy, based on three Buy and one Hold rating over the past three months. With that comes an average PSTV stock price target of $10, representing a potential 5,247.59% upside for the shares.
Business Insider
31-05-2025
- Business
- Business Insider
Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year
The company recognized $1.1M in grant revenue in the first quarter of 2025 compared to $1.7M in in the first quarter of 2024, which represents CPRIT's share of the costs incurred for the REYOBIQ platform advancement for the treatment of patients with LM. 'We improved our cash position in the first quarter as a result of both a financing and grant support,' said Marc Hedrick, M.D., Plus Therapeutics (PSTV) President and Chief Executive Officer. 'With the additional cash and further anticipated grant support in 2025, we are well positioned to make solid progress in our 2 key business goals: enrollment in our REYOBIQ CNS cancer radiotherapeutic clinical trials and the planned launch of the CNSide cerebral spinal fluid assay platform.' Confident Investing Starts Here:
